Research Analysts’ Weekly Ratings Changes for FIGS (FIGS)

A number of research firms have changed their ratings and price targets for FIGS (NYSE: FIGS):

• 8/7/2026 – FIGS had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $16.00 price target on the stock.
• 8/7/2026 – FIGS had its “buy” rating reaffirmed by Roth Capital.
• 8/7/2026 – FIGS had its price target raised by KeyCorp from $19.00 to $20.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – FIGS had its price target raised by Barclays PLC from $17.00 to $20.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – FIGS had its price target lowered by Telsey Advisory Group from $17.00 to $16.00. They now have a “market perform” rating on the stock.
• 8/7/2026 – FIGS had its price target raised by BTIG Research from $20.00 to $22.00. They now have a “buy” rating on the stock.
• 6/23/2026 – FIGS had its “overweight” rating reaffirmed by KeyCorp.

FIGS, Inc operates as a direct-to-consumer designer and retailer of medical apparel and accessories. The company offers a range of products tailored to the needs of healthcare professionals, including scrub sets, lab coats, tops, bottoms, outerwear, footwear, and performance fabrics designed for comfort, durability, and antimicrobial protection. Through its e-commerce platform and a growing network of retail stores, FIGS provides customizable uniforms and accessories with a focus on innovative materials and functional design features such as four-way stretch fabrics, moisture-wicking technology, and multiple secure pockets.

Founded in 2013 by Heather Hasson and Trina Spear, FIGS set out to disrupt the traditional medical uniform market by emphasizing both form and function.